JP2011057670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011057670A5 JP2011057670A5 JP2010189054A JP2010189054A JP2011057670A5 JP 2011057670 A5 JP2011057670 A5 JP 2011057670A5 JP 2010189054 A JP2010189054 A JP 2010189054A JP 2010189054 A JP2010189054 A JP 2010189054A JP 2011057670 A5 JP2011057670 A5 JP 2011057670A5
- Authority
- JP
- Japan
- Prior art keywords
- nervous system
- central nervous
- reducing
- glp
- leukocyte infiltration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23765409P | 2009-08-27 | 2009-08-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011057670A JP2011057670A (ja) | 2011-03-24 |
| JP2011057670A5 true JP2011057670A5 (enExample) | 2013-10-10 |
Family
ID=43384669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010189054A Withdrawn JP2011057670A (ja) | 2009-08-27 | 2010-08-26 | 自己免疫障害を処置するためのグルカゴン様ペプチド−１受容体（ｇｌｐ−１ｒ）アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120148586A1 (enExample) |
| EP (1) | EP2470198A2 (enExample) |
| JP (1) | JP2011057670A (enExample) |
| KR (1) | KR20120050460A (enExample) |
| CN (1) | CN102596229A (enExample) |
| AU (1) | AU2010288191A1 (enExample) |
| BR (1) | BR112012004043A2 (enExample) |
| CA (1) | CA2769835A1 (enExample) |
| IL (1) | IL217967A0 (enExample) |
| IN (1) | IN2012DN00961A (enExample) |
| MX (1) | MX2012002463A (enExample) |
| RU (1) | RU2012106200A (enExample) |
| WO (1) | WO2011024110A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6165168B2 (ja) * | 2011-12-22 | 2017-07-19 | ファイザー・インク | 抗糖尿病化合物 |
| JP2015525226A (ja) | 2012-06-14 | 2015-09-03 | サノフイ | エキセンディン−４ペプチドアナログ |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20140107028A1 (en) * | 2012-10-15 | 2014-04-17 | The University Of Chicago | Methods and compositions for predicting response to glp-1 analogs |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| US20160082137A1 (en) * | 2013-07-25 | 2016-03-24 | Sloan-Kettering Institute For Cancer Research | Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) * | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086731A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| AR098614A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| WO2018069927A1 (en) * | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| WO2018078112A1 (en) * | 2016-10-27 | 2018-05-03 | Aarhus Universitet | Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| WO2018226590A1 (en) * | 2017-06-05 | 2018-12-13 | The Trustees Of Columbia University In The City Of New York | Peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and immunoprofiling in neurodegenerative disease |
| EP3684793A1 (en) | 2017-09-22 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
| MX2020009950A (es) | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Moduladores de receptores acoplados a proteina g. |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023542295A (ja) | 2020-09-14 | 2023-10-06 | リジェネロン ファーマシューティカルズ，インク． | Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用 |
| CA3217720A1 (en) | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| KR20240007251A (ko) | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CA3243669A1 (en) * | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES |
| JP2025510741A (ja) | 2022-03-21 | 2025-04-15 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN119923395A (zh) | 2022-07-27 | 2025-05-02 | 卡莫特医疗有限公司 | N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法 |
| JP2025532651A (ja) | 2022-09-21 | 2025-10-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肥満、糖尿病および肝機能障害を処置する方法 |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| EP4638455A1 (en) | 2022-12-22 | 2025-10-29 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| EP4743174A1 (en) | 2023-07-13 | 2026-05-20 | Aconcagua Bio, Inc. | CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS |
| JP2026526054A (ja) | 2023-07-13 | 2026-08-04 | アコンカグア・バイオ・インコーポレイテッド | 化合物、組成物、および方法 |
| EP4771001A1 (en) | 2023-08-31 | 2026-07-08 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2026041075A1 (en) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| WO2026096926A1 (en) | 2024-11-01 | 2026-05-07 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| US20260199503A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof |
| WO2026156091A1 (en) | 2025-01-15 | 2026-07-23 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| ATE155482T1 (de) | 1990-04-06 | 1997-08-15 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| EP0941114B1 (en) | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
| US6723530B1 (en) | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| AU1190101A (en) | 1999-09-27 | 2001-04-30 | Regents Of The University Of California, The | Engineering antibodies that bind irreversibly |
| US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| WO2003072556A1 (en) * | 2001-06-27 | 2003-09-04 | Prosidion Ltd. | Glutaminyl based dpiv inhibitors |
| EP1411968B1 (en) * | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
| US20060275288A1 (en) * | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| DK2046826T3 (da) | 2006-07-24 | 2011-10-24 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteiner |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| CA2672750A1 (en) | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | Trkb agonists for treating autoimmune disorders |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| US20100261637A1 (en) * | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
-
2009
- 2009-08-19 US US13/392,244 patent/US20120148586A1/en not_active Abandoned
-
2010
- 2010-08-19 CN CN2010800481995A patent/CN102596229A/zh active Pending
- 2010-08-19 RU RU2012106200/15A patent/RU2012106200A/ru not_active Application Discontinuation
- 2010-08-19 MX MX2012002463A patent/MX2012002463A/es not_active Application Discontinuation
- 2010-08-19 BR BR112012004043A patent/BR112012004043A2/pt not_active IP Right Cessation
- 2010-08-19 WO PCT/IB2010/053754 patent/WO2011024110A2/en not_active Ceased
- 2010-08-19 AU AU2010288191A patent/AU2010288191A1/en not_active Abandoned
- 2010-08-19 KR KR1020127004905A patent/KR20120050460A/ko not_active Ceased
- 2010-08-19 IN IN961DEN2012 patent/IN2012DN00961A/en unknown
- 2010-08-19 EP EP10754580A patent/EP2470198A2/en not_active Withdrawn
- 2010-08-19 CA CA2769835A patent/CA2769835A1/en not_active Abandoned
- 2010-08-26 JP JP2010189054A patent/JP2011057670A/ja not_active Withdrawn
-
2012
- 2012-02-06 IL IL217967A patent/IL217967A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2175853A4 (en) | METHOD OF TREATING METABOLIC SYNDROME WITH DOPAMINE RECEPTOR AGONISTS | |
| JP2013525444A5 (enExample) | ||
| LTPA2018002I1 (lt) | Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius | |
| JP2007527914A5 (enExample) | ||
| EP2300037A4 (en) | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR | |
| ECSP10010684A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad. | |
| EP2528618A4 (en) | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS | |
| EP2603215A4 (en) | NEW D3 DOPAMINE RECEPTOR AGONISTS FOR THE TREATMENT OF DYSKINESIA AT MORBUS PARKINSON | |
| EP2496249A4 (en) | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| JP2015501783A5 (enExample) | ||
| EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
| LT2513053T (lt) | Pirolidino karboksirūgščių dariniai kaip su g baltymu sąveikaujančio receptoriaus 43 (gpr43) agonistai, farmacinės kompozicijos ir būdai, skirti naudoti metabolinių susirgimų gydymui | |
| JP2011527332A5 (enExample) | ||
| ZA201103044B (en) | Conjugates of glp-1 agonists and uses thereof | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| IL261019B (en) | Antibodies to 6-il and their use | |
| PL2301525T3 (pl) | Preparat ibuprofenu do stosowania miejscowego | |
| JP2012519182A5 (enExample) | ||
| CL2012000263A1 (es) | Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. | |
| JP2015514739A5 (enExample) | ||
| EP2146720A4 (en) | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINE AND THEIR USE FOR THE RECOURSE-INHIBITION OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE | |
| JP2008013542A5 (enExample) | ||
| HUE037300T2 (hu) | Szerotonin 5-HT3 receptor antagonisták lezionális vesztibuláris zavarok kezelésében való felhasználásra | |
| JP2012516348A5 (enExample) |